|
 |
RaplonThis page contains recent news articles, when available, and an overview of Raplon but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.FDA recently approved for marketing the human drug product RAPLON (Rapacuronium ... RAPLON is indicated as an adjunct to general anesthesia to facilitate ... Pay-Per-View - Federal Register 2007 - Loislaw Organon Whistleblower Defends His Claims - Aug 5, 2008 1) the harmful effects of Raplon have been in the public domain for 7 years ... Dr. Feldstein does not need to have been directly involved with Raplon to ... Pharmalot Did Schering-Plough Properly Review Organon Deal? - Jun 30, 2008 A former Organon employee alleges that Organon failed to disclose to the FDA concerns about serious bronchospasm that were cited by Raplon clinical trial ... Pharmalot Namibia: Let's Protect Others from Life-threatening Disease - Jun 17, 2005 The other drug was Raplon (rapa-curonium bromide), an injectable anesthesia drug ... Risks of taking Raplon were the inability to breathe normally, ... AllAfrica.com Press Release: Eslax(R) (Rocuronium Bromide) Approved in Japan. - PR ... - Aug 1, 2007 Article: FDA Approves Organon's RAPLON(TM), the First Anesthesia ... ... RAPLON adds to Organon's profile of neuromuscular ... agents is ZEMURON(R) ... Pay-Per-View - PR Newswire - HighBeam Research Organon Concealed Bleeding Data For Arixtra - Apr 24, 2008 Both the Arixtra and Raplon episodes, by the way, took place while Schering-Plough's senior vp for global fertility, Hans Vemer, headed Organon. ... Pharmalot Press Release: FDA Clears Silver-Coated Breathing Tube for Marketing ... - Nov 9, 2007 RAPLON was administered in hospital and other surgical settings as a muscle relaxant for breathing tube placement and surgery. Other drugs on the market may ... Pay-Per-View - M2 Presswire - HighBeam Research |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |